Clinical trials: Biological Therapy
Ovarian Cancer Recurrent
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial…
- Trial name
- NCT03657966
- Testing
- DCVAC/OvCa, Standard of Care Chemotherapy
- Where
- 8 sites in Czechia
- Volunteers
- 33 people
- Sponsor
- SOTIO a.s.
Spondyloarthritis, Treatment Adherence
Pharmaceutical Intervention and Adherence to bDMARDs in Spondyloarthritis.
There is a lack of knowledge among patients concerning their treatment with bDMARDs, which could lead to low adherence. The objective of this study is to assess the impact of a pharmacist's intervention on the adherence to…
- Trial name
- SPADHESION (NCT04001673)
- Testing
- Pharmacist's intervention
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Dr Ornella Conort
Heparin-induced Thrombocytopenia
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment, it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis recurrence, amputation and death approaching 52…
- Trial name
- Score-TIH (NCT00748839)
- Where
- 27 sites in France
- Volunteers
- 2,700 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
IBD Patients, Originator Treatment, Biosimilar, Switch Back
A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar
Biosimilars represent great potential in cost saving and reinvestment opportunities in healthcare. Biosimilars of adalimumab appear to be clinically equivalent to the reference product in patients with rheumatoid arthritis and…
- Trial name
- Rhoneswitch (NCT04422171)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Grenoble
Rheumatoid Arthritis
The RA PROTECTION Study
This is a prospective, multi-center, double-blind, randomized, controlled pilot study to assess safety and efficacy of the Vorso PROTECT System in patients who have moderately to severely active rheumatoid arthritis.
- Trial name
- NCT04306744
- Testing
- Vorso PROTECT System
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Nesos Corp
Atopic Dermatitis
BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis
The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and…
- Trial name
- BioDay (NCT03549416)
- Where
- 14 sites in Netherlands
- Volunteers
- 1,200 people
- Sponsor
- UMC Utrecht
Leukemia, Lymphoma
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002553
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, low-LET cobalt-60 gamma ray therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Psoriasis, Psoriatic-arthritis
PsoBest - The German Psoriasis Registry
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
- Trial name
- NCT01848028
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Obstructive Pulmonary Disease, COPD
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
- Trial name
- ROMEO (NCT07566195)
- Testing
- Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
- Where
- 13 sites in France
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Breast Cancer
Clinico-biological Data Collection Study of Metastatic Breast Cancer
RATIONALE : Currently, the mechanisms associated with the response or resistance to treatment are poorly understood and are multifactorial.
- Trial name
- EPICURE_SEIN (NCT03958136)
- Testing
- Metastasis biopsy, Biomarkers blood, urine and microbiota samples, Patient Reported Outcome (PRO)
- Where
- 2 sites in France
- Volunteers
- 289 people
- Sponsor
- Institut Cancerologie de l'Ouest
Multiple Osteochondromas
Registry of Multiple Osteochondromas
REM is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains…
- Trial name
- REM (NCT04133285)
- Where
- Italy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Luca Sangiorgi
Cancer
Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor activity of NCP-IL-22BP mRNA, a non-cationic peptide-delivered mRNA encoding…
- Trial name
- NCT07562815
- Testing
- 25 μg NCP-IL-22BP mRNA, 50 μg NCP-IL-22BP mRNA, 100 μg NCP-IL-22BP mRNA
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Atopic Dermatitis
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.
- Trial name
- NCT04895423
- Testing
- Methotrexate therapy, Mycophenolate mofetil therapy, Cyclosporine therapy
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
HIV, HIV-associated Neurocognitive Disorder
Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen
In this study investigators will use a multi-modal imaging approach of MRS and fMRI to comprehensively assess the biological changes in the brain associated with EFV-based regimen (EFV/FTC/TDF), specifically alterations in the…
- Conditions
- HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
- Trial name
- NCT01978743
- Testing
- Raltegravir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer
It has been found that many breast cancers are hormone dependent and that hormonal therapy by estrogen suppression such as ovarian ablation, tamoxifen and aromatase inhibitor has proven beneficial in both adjuvant and neoadjuvant…
- Trial name
- NCT00488722
- Testing
- Zoladex
- Where
- China
- Sponsor
- Tianjin Medical University
Allergic Rhinitis
A Novel Biologic Therapy for Perennial Allergic Rhinitis
This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered…
- Trial name
- NCT03360071
- Testing
- Allergen Immunotherapy Extract, Allergen Immunotherapy Control
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Major Depressive Disorder
Brain GABA Levels and Treatment Response in Major Depressive Disorder
This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.
- Trial name
- NCT00464711
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Rheumatoid Arthritis, Tuberculosis
Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy
This research will help doctors interested in the usefulness of a new test to discover hidden tuberculosis infections in patients diagnosed with rheumatoid arthritis (RA). This new test is called Quantiferon-Gold (QFT-G).
- Trial name
- NCT00925249
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Medical Center
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV…
- Trial name
- NCT00012064
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Lisata Therapeutics, Inc.
Rheumatoid Arthritis
Umbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, pain, and functional disability.
- Trial name
- SECRETOME-RA (NCT07715045)
- Testing
- Umbilical Cord-Derived Mesenchymal Stromal Cell (UC-MSC) Secretome
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Sriwijaya
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.